Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1

There are many patients who do not respond to immune checkpoint inhibitor (ICI) immunotherapy. Here, the authors show a significant negative correlation between sphingosine kinase-1 (SK1) expression and survival for ICI-treated melanoma patients, and further show that targeting SK1 improves response...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Caroline Imbert, Anne Montfort, Marine Fraisse, Elie Marcheteau, Julia Gilhodes, Elodie Martin, Florie Bertrand, Marlène Marcellin, Odile Burlet-Schiltz, Anne Gonzalez de Peredo, Virginie Garcia, Stéphane Carpentier, Sophie Tartare-Deckert, Pierre Brousset, Philippe Rochaix, Florent Puisset, Thomas Filleron, Nicolas Meyer, Laurence Lamant, Thierry Levade, Bruno Ségui, Nathalie Andrieu-Abadie, Céline Colacios
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/38bb744217484cb7ab770593454d6238
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:38bb744217484cb7ab770593454d6238
record_format	dspace
spelling	oai:doaj.org-article:38bb744217484cb7ab770593454d62382021-12-02T17:32:29ZResistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-110.1038/s41467-019-14218-72041-1723https://doaj.org/article/38bb744217484cb7ab770593454d62382020-01-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-14218-7https://doaj.org/toc/2041-1723There are many patients who do not respond to immune checkpoint inhibitor (ICI) immunotherapy. Here, the authors show a significant negative correlation between sphingosine kinase-1 (SK1) expression and survival for ICI-treated melanoma patients, and further show that targeting SK1 improves response to ICI in mouse cancer models.Caroline ImbertAnne MontfortMarine FraisseElie MarcheteauJulia GilhodesElodie MartinFlorie BertrandMarlène MarcellinOdile Burlet-SchiltzAnne Gonzalez de PeredoVirginie GarciaStéphane CarpentierSophie Tartare-DeckertPierre BroussetPhilippe RochaixFlorent PuissetThomas FilleronNicolas MeyerLaurence LamantThierry LevadeBruno SéguiNathalie Andrieu-AbadieCéline ColaciosNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Caroline Imbert Anne Montfort Marine Fraisse Elie Marcheteau Julia Gilhodes Elodie Martin Florie Bertrand Marlène Marcellin Odile Burlet-Schiltz Anne Gonzalez de Peredo Virginie Garcia Stéphane Carpentier Sophie Tartare-Deckert Pierre Brousset Philippe Rochaix Florent Puisset Thomas Filleron Nicolas Meyer Laurence Lamant Thierry Levade Bruno Ségui Nathalie Andrieu-Abadie Céline Colacios Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
description	There are many patients who do not respond to immune checkpoint inhibitor (ICI) immunotherapy. Here, the authors show a significant negative correlation between sphingosine kinase-1 (SK1) expression and survival for ICI-treated melanoma patients, and further show that targeting SK1 improves response to ICI in mouse cancer models.
format	article
author	Caroline Imbert Anne Montfort Marine Fraisse Elie Marcheteau Julia Gilhodes Elodie Martin Florie Bertrand Marlène Marcellin Odile Burlet-Schiltz Anne Gonzalez de Peredo Virginie Garcia Stéphane Carpentier Sophie Tartare-Deckert Pierre Brousset Philippe Rochaix Florent Puisset Thomas Filleron Nicolas Meyer Laurence Lamant Thierry Levade Bruno Ségui Nathalie Andrieu-Abadie Céline Colacios
author_facet	Caroline Imbert Anne Montfort Marine Fraisse Elie Marcheteau Julia Gilhodes Elodie Martin Florie Bertrand Marlène Marcellin Odile Burlet-Schiltz Anne Gonzalez de Peredo Virginie Garcia Stéphane Carpentier Sophie Tartare-Deckert Pierre Brousset Philippe Rochaix Florent Puisset Thomas Filleron Nicolas Meyer Laurence Lamant Thierry Levade Bruno Ségui Nathalie Andrieu-Abadie Céline Colacios
author_sort	Caroline Imbert
title	Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
title_short	Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
title_full	Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
title_fullStr	Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
title_full_unstemmed	Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
title_sort	resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/38bb744217484cb7ab770593454d6238
work_keys_str_mv	AT carolineimbert resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT annemontfort resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT marinefraisse resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT eliemarcheteau resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT juliagilhodes resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT elodiemartin resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT floriebertrand resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT marlenemarcellin resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT odileburletschiltz resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT annegonzalezdeperedo resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT virginiegarcia resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT stephanecarpentier resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT sophietartaredeckert resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT pierrebrousset resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT philipperochaix resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT florentpuisset resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT thomasfilleron resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT nicolasmeyer resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT laurencelamant resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT thierrylevade resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT brunosegui resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT nathalieandrieuabadie resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1 AT celinecolacios resistanceofmelanomatoimmunecheckpointinhibitorsisovercomebytargetingthesphingosinekinase1
_version_	1718380241218437120

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1

Ejemplares similares